K 103 IP
Alternative Names: K-103-IP; K-103-PALatest Information Update: 26 Sep 2019
At a glance
- Originator Kowa Pharmaceutical
 - Class Analgesics; Anti-inflammatories
 - Mechanism of Action Cyclooxygenase inhibitors
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- Discontinued Acute pain; Inflammation
 
Most Recent Events
- 26 Sep 2019 Discontinued - Phase-III for Acute pain in China (Topical)
 - 26 Sep 2019 Discontinued - Phase-III for Acute pain in USA (Topical)
 - 26 Sep 2019 Discontinued - Phase-III for Inflammation in USA (Topical)